Published on in Vol 15 (2026)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/76815, first published .
Efficacy, Safety, and Economic Impact of Cytisinicline Maintenance Therapy in Patients Who Are Candidates for Smoking Cessation: Protocol for a Phase IV, Multicenter, Randomized, Open-Label, Controlled, Parallel Clinical Trial (CITISILONG Trial)

Efficacy, Safety, and Economic Impact of Cytisinicline Maintenance Therapy in Patients Who Are Candidates for Smoking Cessation: Protocol for a Phase IV, Multicenter, Randomized, Open-Label, Controlled, Parallel Clinical Trial (CITISILONG Trial)

Efficacy, Safety, and Economic Impact of Cytisinicline Maintenance Therapy in Patients Who Are Candidates for Smoking Cessation: Protocol for a Phase IV, Multicenter, Randomized, Open-Label, Controlled, Parallel Clinical Trial (CITISILONG Trial)

Carlos Rabade Castedo   1, 2 , PhD ;   Ana Estany-Gestal   3 * , PhD ;   Carlos A Jiménez Ruiz   4 * , PhD ;   José Ignacio de Granda-Orive   5, 6 * , PhD ;   Juan Antonio Riesco-Miranda   7, 8, 9 * , MSc ;   María Isabel Cristóbal Fernández   4 * , MSc ;   Angela Ramos-Pinedo   10 * , MSc ;   Jaime Signes-Costa Miñana   11, 12 , PhD ;   María Inmaculada Gorordo-Unzueta   13, 14 * , MSc ;   Agustin Valido-Morales   15 , PhD ;   Jacobo Sellarés -Torres   16 * , PhD ;   Eva Cabrera-César   17 * , PhD ;   Alejandro Frino-García   16 , MSc ;   Luis Valdés Cuadrado   1, 2, 18 , PhD

1 Department of Pulmonology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain

2 Health Research Institute, Santiago de Compostela, La Coruña, Spain

3 Research Methodology Unit, Health Research Institute, Santiago de Compostela, Galicia, Spain

4 Smoking Cessation Unit, Hospital Clínico San Carlos, Madrid, Spain

5 Department of Pulmonology, Hospital Universitario 12 De Octubre, Madrid, Spain

6 Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain

7 Department of Pulmonology, Hospital San Pedro de Alcántara, Cáceres, Spain

8 Extremadura University Institute of Biosanitary Research, Cáceres, Spain

9 Centre for Networked Research on Respiratory Diseases (CIBERES), Madrid, Spain

10 Department of Pulmonology, Hospital Universitario Fundación Alcorcón, Madrid, Spain

11 Department of Pulmonology, Hospital Clínico Universitario de Valencia, Valencia, Spain

12 INCLIVA Health Research Institute, Valencia, Spain

13 Department of Pulmonology, Hospital Universitario Galdakao-Usánsolo, Bilbao, Spain

14 Biobizkaia Health Research Institute, Bilbao, Spain

15 Department of Pulmonology, Hospital Universitario Virgen Macarena, Valencia, Spain

16 Department of Pulmonology, Hospital Clínic de Barcelona, Barcelona, Spain

17 Department of Pulmonology, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain

18 Department of Medicine, Universidade de Santiago de Compostela, Santiago de Compostela, Spain

*these authors contributed equally

Corresponding Author:

  • Carlos Rabade Castedo, PhD
  • Department of Pulmonology
  • Complejo Hospitalario Universitario de Santiago
  • Travesía da Choupana S/N
  • Santiago de Compostela 15706
  • Spain
  • Phone: 34 981950000 ext 250000
  • Email: crabcas1@gmail.com